Trademark: 97978410
Word
ENTOS
Status Date
Tuesday, September 3, 2024
Filing Date
Wednesday, September 14, 2022
Published for Opposition
Tuesday, September 3, 2024
40 Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for
others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and
antibodies
44 Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus
diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and
patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic,
prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely,
providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be
treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines,
recombinant proteins and antibodies; genetic testing for medical purpose
42 Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines
and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research
purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical
and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific
research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product
development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical
devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic
use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein
platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific
research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals,
pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding
clinical trial studies on new vaccine candidates
The mark consists of the word "entos" and to the right three concentric rings of circles with the circles increasing in diameter from the inner ring to the outer ring.
Color is not claimed as a feature of the mark.
Sep 17, 2022
New Application Entered
Sep 29, 2022
New Application Office Supplied Data Entered
Jun 27, 2023
Non-Final Action Written
Sep 27, 2023
Application Extension To Response Period - Received
Sep 27, 2023
Application Extension Granted/Receipt Provided
Nov 16, 2023
Divisional Request Received
Sep 30, 2022
Notice Of Design Search Code E-Mailed
Jun 26, 2023
Assigned To Examiner
Jun 27, 2023
Non-Final Action E-Mailed
Nov 16, 2023
Teas Response To Office Action Received
Jun 27, 2023
Notification Of Non-Final Action E-Mailed
Nov 16, 2023
Teas Request To Divide Received
Apr 6, 2024
Assigned To Lie
Jun 12, 2024
Case Assigned To Intent To Use Paralegal
Jun 25, 2024
Divisional Processing Complete
Jul 25, 2024
Approved For Pub - Principal Register
Aug 14, 2024
Notification Of Notice Of Publication E-Mailed
Sep 3, 2024
Published For Opposition
Sep 3, 2024
Official Gazette Publication Confirmation E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
